Company news
Mustang Bio, Inc. news in 2019
Mustang Bio, Inc.'s news releases, calls and decks from 2019, newest first.
Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
December 8, 2019
Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
November 11, 2019
Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting
November 5, 2019
Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma
October 23, 2019
Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
September 22, 2019